Insight Molecular Diagnostics (IMDX) Net Margin (2020 - 2026)

Insight Molecular Diagnostics has disclosed Net Margin across 7 years of filings, most recently posting 13790.62% for Q1 2026.

• Net Margin for Q1 2026 came in at 13790.62%, down 1347860.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 2460.95% (down 94490.0% YoY), and the FY2025 annual result was 1238.52%, up 200050.0% from the prior year.
• Net Margin came in at 13790.62% for Q1 2026 at Insight Molecular Diagnostics, down from 2015.36% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 3316.06% in Q4 2022 to a low of 14368.66% in Q3 2022.
• The 5-year median for Net Margin is 2708.16% (2022), against an average of 4165.88%.
• Across the five-year window, Net Margin surged 1280992 bps in 2023 and plunged 1347860 bps in 2026, its largest moves.
• Insight Molecular Diagnostics' Net Margin stood at 3316.06% in 2022, then plunged by 227 bps to 4225.8% in 2023, then jumped by 47 bps to 2255.11% in 2024, then advanced by 11 bps to 2015.36% in 2025, then slumped by 584 bps to 13790.62% in 2026.
• The last three Net Margin figures came in at 13790.62% (Q1 2026), 2015.36% (Q4 2025), and 4174.62% (Q3 2025), per Business Quant data.